Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
VTYX Price/Volume Stats
| Current price | $2.25 | 52-week high | $4.82 |
| Prev. close | $1.99 | 52-week low | $0.78 |
| Day low | $1.91 | Volume | 3,920,600 |
| Day high | $2.28 | Avg. volume | 1,359,809 |
| 50-day MA | $1.33 | Dividend yield | N/A |
| 200-day MA | $1.88 | Market Cap | 160.11M |
VTYX Stock Price Chart Interactive Chart >
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTYX Price Returns
| 1-mo | 85.95% |
| 3-mo | 51.01% |
| 6-mo | -27.88% |
| 1-year | -31.51% |
| 3-year | -85.93% |
| 5-year | N/A |
| YTD | 2.74% |
| 2024 | -11.34% |
| 2023 | -92.47% |
| 2022 | 65.11% |
| 2021 | N/A |
| 2020 | N/A |